1APZ image
Deposition Date 1995-06-14
Release Date 1996-12-23
Last Version Date 2024-10-23
Entry Detail
PDB ID:
1APZ
Title:
HUMAN ASPARTYLGLUCOSAMINIDASE COMPLEX WITH REACTION PRODUCT
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
2.30 Å
R-Value Free:
0.29
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 61
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:ASPARTYLGLUCOSAMINIDASE
Gene (Uniprot):AGA
Chain IDs:A, C
Chain Length:162
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:ASPARTYLGLUCOSAMINIDASE
Gene (Uniprot):AGA
Chain IDs:B, D
Chain Length:141
Number of Molecules:2
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
ASN A ASN GLYCOSYLATION SITE
Primary Citation
Three-dimensional structure of human lysosomal aspartylglucosaminidase.
Nat.Struct.Biol. 2 1102 1108 (1995)
PMID: 8846222 DOI: 10.1038/nsb1295-1102

Abstact

The high resolution crystal structure of human lysosomal aspartylglucosaminidase (AGA) has been determined. This lysosomal enzyme is synthesized as a single polypeptide precursor, which is immediately post-translationally cleaved into alpha- and beta-subunits. Two alpha- and beta-chains are found to pack together forming the final heterotetrameric structure. The catalytically essential residue, the N-terminal threonine of the beta-chain is situated in the deep pocket of the funnel-shaped active site. On the basis of the structure of the enzyme-product complex we present a catalytic mechanism for this lysosomal enzyme with an exceptionally high pH optimum. The three-dimensional structure also allows the prediction of the structural consequences of human mutations resulting in aspartylglucosaminuria (AGU), a lysosomal storage disease.

Legend

Protein

Chemical

Disease

Primary Citation of related structures